Kentucky Access to Recovery Evaluation

April 11, 2025 updated by: Terry Bunn

Evaluation of the Kentucky Access to Recovery (KATR) Linkage Strategy

Evaluate the long-term effectiveness of implementing vouchers as a linkage strategy in a population requiring recovery support services (RSS) when no other funding sources are available. A within-subjects study design will be used to test the effectiveness of the Kentucky Access to Recovery (KATR) last resort voucher linkage approach to reduce the risk of nonfatal and fatal overdoses by (a) increasing an individual's recovery capital; (b) reducing resumption of illicit substance use; and (c) promoting relinking to RSSs if illicit substance use is resumed.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

458

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Kentucky
      • Berea, Kentucky, United States, 40403
        • FAHE
      • Lexington, Kentucky, United States, 40506
        • University Of Kentucky

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

individuals in underserved areas with incomes at or below the 200% poverty level, individuals with prior criminal-justice involvement, veterans, and pregnant and parenting populations, with illicit SUD

Description

Inclusion Criteria:

  • be in SUD treatment or have completed within the past year SUD treatment for opioid use disorder or stimulant use disorder or have a history of overdose from opioid use
  • be a first-time participant in KATR
  • be in early stages of recovery (less than one year in recovery)
  • be a resident of a KATR service county
  • be at or below the 200% federal poverty level
  • not have financial resources available through other funding mechanisms for RSSs
  • be 18 years of age and older
  • be in need of recovery supports that will enhance their likelihood of staying in recovery

Exclusion Criteria:

  • Under 18
  • Participated in KATR previously

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
KATR Clients
participants in the early stages of recovery and in substance use disorder (SUD) treatment; or those that have completed within the past year SUD treatment for opioid use disorder or stimulant use disorder or have a history of overdose from opioid use.
Behavioral: KATR Linkage Strategy

The Kentucky ATR (KATR) strategy is a 25-county program that links county residents at or below the 200% national poverty level who have an illicit SUD and are in treatment or early recovery to evidence-based RSSs such as recovery housing, and to other RSSs.

The KATR linkage approach uses vouchers as a linkage strategy for individuals in SUD treatment who have no other funding options to acquire critical RSSs. As such, KATR's linkage through vouchers is a "last resort" approach for linking to RSSs.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Recovery Capital per person
Time Frame: Enrollment, Up to 6 months, 3 months post discharge, and 12 months post enrollment
Recovery capital will be assessed using the Brief Assessment of Recovery Capital-10 (BARC-10); 10 item survey unidimensional measure of recovery capital, scores may range from 6-60 at any given time. Evaluation of the measure suggests that individuals who have a higher score are likely to reach or sustain a year or longer of recovery from substance use disorder.
Enrollment, Up to 6 months, 3 months post discharge, and 12 months post enrollment
Change in number of drug overdoses per person
Time Frame: Enrollment, Up to 6 months, 3 months post discharge, and 12 months post enrollment
Number of drug overdoses will be assessed with the following survey question: In the past 30 days, did you experience an overdose or take too much of a substance that resulted in needing supervision or medical attention?
Enrollment, Up to 6 months, 3 months post discharge, and 12 months post enrollment
Change in number of days of illicit substance use per person
Time Frame: Enrollment, Up to 6 months, 3 months post discharge, and 12 months post enrollment
Number of days illicit substance use will be assessed with the following survey question: During the past 30 days, how many days have you used any substance
Enrollment, Up to 6 months, 3 months post discharge, and 12 months post enrollment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Terry Bunn

Investigators

  • Principal Investigator: Terry Bunn, PhD, University Of Kentucky

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 3, 2023

Primary Completion (Actual)

February 24, 2025

Study Completion (Actual)

February 24, 2025

Study Registration Dates

First Submitted

May 23, 2023

First Submitted That Met QC Criteria

June 1, 2023

First Posted (Actual)

June 5, 2023

Study Record Updates

Last Update Posted (Actual)

April 16, 2025

Last Update Submitted That Met QC Criteria

April 11, 2025

Last Verified

April 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 81811
  • R01CE003513-01-00 (Other Grant/Funding Number: CDC)
  • R01CE003513-01 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe